Oct 21, 2019
Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019
Oct 03, 2019
FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic
Sep 30, 2019
Celltrion to Launch TemixysTM Double Combination Once-Daily Tablet for HIV Treatment in the U.S.
Aug 14, 2019
Non-Invasive Cellulite Treatments and Devices Dominating Billion Dollar Market
Aug 08, 2019
Lawsuits against drugmaker Gilead over HIV medications containing TDF to be coordinated before a single judge in California, following motion by Grant & Eisenhofer
Jul 08, 2019
Grant & Eisenhofer Brings Mass Tort Lawsuits against Drugmaker Gilead over HIV Medications Containing TDF, Suits Move Forward in California State Court
May 14, 2019
Hilliard & Shadowen, LLP Report Coalition Of Consumers, Activists, And Payors Sues Gilead And Other Manufacturers For Anticompetitive Practices On HIV Medicines
Apr 30, 2019
Taiwan National Health Insurance Administration of the Ministry of Health and Welfare Approves Vemlidy(R) (tenofovir alafenamide) for Reimbursement
Apr 19, 2019
Mass Tort Alleges Gilead Sciences, Inc. Withheld Safer Drugs From HIV/AIDS Patients, Manipulated Patent Timing for Profit, Announces Jenner Law
Dec 21, 2018
Viriom to Report Results from Phase 1b Clinical Trial of Once Weekly Oral HIV Treatment
Oct 03, 2018
Hong Kong Department of Health Approves Biktarvy(R) (bictegravir, emtricitabine, tenofovir alafenamide)
Jul 05, 2018
ContraVir Pharmaceuticals to Present at Virtual Investor Conference
May 02, 2018
The Medicines Patent Pool Adds New Suppliers from South Africa and South Korea to its Growing Generic Manufacturing Network
Mar 28, 2018
Mylan Introduces Symfi(TM) Triple Combo Once-Daily HIV Treatment in the U.S.
Mar 02, 2018
Mylan to Introduce Two New Cost-Saving HIV Combination Treatments in the U.S.
Feb 20, 2018
Mylan Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program
Nov 21, 2017
Janssen Announces U.S. FDA Approval of First and Only Complete, Single-Pill, Two-Drug Regimen, JULUCA® (Dolutegravir and Rilpivirine), for the Treatment of HIV-1 Infection
Oct 25, 2017
Investigational Darunavir-Based Single-Tablet Regimen Shows Positive Results in Previously Untreated HIV Patients in Pivotal Phase 3 AMBER Clinical Trial
Oct 04, 2017
MYR GmbH Announces Presentation of Interim Results of Phase 2b Clinical Program of Myrcludex B at the American Association for the Study of Liver Diseases Conference
Sep 25, 2017
Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1